Bettina Hamelin

Bettina Hamelin is the President of Innovative Medicines Canada (IMC), having assumed the role on April 8, 2024. She holds a Doctor of Pharmacy (PharmD) degree and an Executive MBA in Healthcare from the University of British Columbia. With over 30 years of experience in academia, industry, and non-profit organizations, Dr. Hamelin is recognized as a leader in the life sciences sector.

Career Highlights

• Previous Roles: Before joining IMC, Dr. Hamelin was the President and CEO of Ontario Genomics, where she significantly advanced the organization's role in engineering biology. She has also served as Vice President at the Natural Sciences and Engineering Research Council of Canada (NSERC), focusing on public-private partnerships and research innovation. Her earlier career includes leadership positions at BioChem Pharma and Pfizer, as well as a decade as a tenured professor at Université Laval.123

• Current Focus: As President of IMC, Dr. Hamelin is committed to enhancing access to innovative medicines for Canadians and promoting Canada as a hub for life sciences investments and clinical trials. She emphasizes the importance of collaboration among stakeholders to drive healthcare innovation.12

Contributions and Advocacy

Dr. Hamelin is actively involved in various committees and boards aimed at advancing research and innovation in Canada. She serves as a Board Director at the Centre for Probe Development and Commercialization and chairs the National Engineering Biology Steering Committee.2 Her advocacy efforts are directed towards ensuring that Canada's pharmaceutical sector is prepared to adopt new innovations that can improve public health.23

Personal Attributes

Fluent in three languages, Dr. Hamelin combines her extensive knowledge with a passion for improving health outcomes in Canada, making her a trusted figure in the pharmaceutical industry.12